{"schema_version":"secwatch.filing_event.v1","accession":"0001516551-24-000052","form_type":"8-K","ticker":"SKYE","cik":"0001516551","company_name":"Skye Bioscience, Inc.","filed_at":"2024-04-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.775016+00:00","generated_at":"2026-06-04T02:49:26.073407+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Skye Bioscience reports pro forma equity >$5M after $90M private placement","bullets":["Closed private placement of 15.7M shares and 10.0M pre-funded warrants for $90M gross ($83.5M net).","Sold real estate held by subsidiary Avalite Sciences, recording $1.14M gain in pro forma.","Pro forma stockholders' equity rises to $82.5M from ($2.1M) deficit at Dec 31, 2023.","Company believes it now meets Nasdaq's $5M minimum equity requirement for initial listing."],"urls":{"canonical":"https://secwatch.observer/filing/0001516551-24-000052","json":"https://secwatch.observer/filing/0001516551-24-000052.json","markdown":"https://secwatch.observer/filing/0001516551-24-000052.md","text":"https://secwatch.observer/filing/0001516551-24-000052.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1516551/000151655124000052/0001516551-24-000052-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1516551/000151655124000052/skye-20240403.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T02:49:26.073407+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}